Conflict of interest
|
|
- Osborne Ford
- 6 years ago
- Views:
Transcription
1 Hyperkalemia in Heart and Kidney patients: Rescue is here Wajeh Qunibi, MD, FACP Professor of Medicine University of Texas Health Science Center San Antonio, TX CARDIORENAL CONNECTION April 28, 2017 Conflict of interest Research grant from ZS Pharma
2 Objectives Discuss the prevalence of hyperkalemia in heart and kidney patients Discuss novel agents for treatment of hyperkalemia Challenges in Hyperkalemia studies Definition of hyperkalemia Serum [K+] > 5.0 meq/l > 5.5 meq/l > 6.0 meq/l Hemolyzed specimens Prevalence varies with level of GFR in different studies Outcomes of hyperkalemia by serum K+ level: Short-term vs long-term outcomes EKG changes
3 Prevalence of Hyperkalemia (serum K > 5.0 meq/l) HK is in the general population: < 1% of normal healthy adults 2.6% of emergency department visits 1-10% of hospital admissions Prevalence significantly higher in CKD: 7.7% to 83% Patients at highest risk for HK are those taking RAASi with CKD stage 3 or greater who also have DM, HF or both. Use of renin angiotensin aldosterone system (RAAS) inhibitors contribute to hyperkalemia in 35-75% of all cases Source: 1Jain et al, 2012; 2McMahon et al, 2012; 3Makani et al, 2013; 4Takaichi et al, 2007; 5Fondjour et al, Drugs blocking the Renin Angiotensin Aldosterone System causing hyperkalemia due to decreased renal K excretion Direct renin inhibitors Palmer. NEJM 2004
4 Risk of Hyperkalemia (K+ > 5.5 meq/l) in non-diabetic hypertensive patients with CKD receiving RAASi by baseline GFR in the AASK Trial N = 1094 nondiabetic adults with hypertensive CKD from AASK FU = 3.0 to 6.4 years Weinberg et al. Arch I Med 2009 Incidence of Hyperkalemia ( 5.5) in Veterans with and without CKD % of patients Retrospective analysis of 245,808 inpatient and outpatient veterans (with at least 1 hospitalization and 1 serum K+ record in ) No CKD Stage 3 Stage 4 Stage 5 15,485/174,935* 11,958/57,798* 3,516/8,351* 2,678/4,724* *Number of patients with hyperkalemia divided by number of patients in each respective cohort. Of the hyperkalemic events (3.2% of records), more occurred as inpatient events [52.7%]) than as outpatient events (47.3%) Einhorn LM, et al. Arch Intern Med. 2009;169(12):
5 Incidence of Hyperkalemia ( 5.5) in Veterans with and without CKD by RAASi use 40% 41% 30% % of patients 20% 10% 5.3% 8.7% 18% No RAASi RAASi 0% No RAASi RAASi No CKD CKD Einhorn LM, et al. Arch Intern Med. 2009;169(12): Hyperkalemia associated RAAS inhibitor use in selected clinical trials in patients with CKD
6 Increased Rate of Hospitalization in HF Patients on MRAs after the publication of Randomized Aldactone Evaluation Study (RALES) in % reduction in mortality Spironolactone prescriptions Pitt et al. NEJM 1999 Hospital admission for hyperkalemia In-Hospital mortality from hyperkalemia Juurlink et al. NEJM 2004 Hyperkalemia in a cohort of patients with newly diagnosed heart failure N = 19,194 patients with newly diagnosed HF Age: 1 89 years HK identified in 11.3% of patients during follow-up of 3.9 years Risk factors for HK: Renal failure Type II diabetes Valvular heart disease Use of potassium-sparing diuretics ACE inhibitors Trimethoprim Non-steroidal anti-inflammatory drugs Drug combinations. The risk was highest within the first month of medication use Michel et al. European Journal of Heart Failure (2015) 17,
7 Hyperkalemia in Heart Failure patients increases as Renal Function declines particularly in MRA-treated patients Chaudry et al. JACC 68, Issue 14, 2016, WRF: Worsening renal function HK is more frequent in stage 3 diabetic CKD patients than in non-diabetic CKD patients Loutradis et al. Am J Nephrol 2015;42: patients with CKD 180 patients with CKD HK defined as K+ > 5.0 meq/l
8 Increased mortality risk within 1 day of moderate (Serum K 5.5 and <6.0) and severe ( 6.0 meq/l) hyperkalemia Einhorn et al. Arch I Med 2009 The reference group: Patients with K+ <5.5 meq/l) and no CKD Study cohort: 245,808 patients from VA 2,103,422 K records 70,873 (28.8%) had CKD 66% on ACEI/ARB 50% had DM 2.4% od patients died within 1 day Graded In-Hospital mortality increase with higher serum K+ level particularly in ND-CKD patients Grodzinsky et al. Am J Med 129, Issue 8, 2016,
9 In hospital mortality based on number of hyperkalemia in events in CKD patients with AMI Grodzinsky et al. Am J Med 129, Issue 8, 2016, Serum Potassium Levels and Mortality in Acute Myocardial Infarction patients with confirmed AMI U-shaped relationship between mean post-admission serum K+ level and in-hospital mortality Lowest mortality observed with post-admission serum K+ levels between 3.5 and <4.5 meq/l Goyal et al. JAMA. 2012;307(2):
10 Associations between serum potassium (K+) (meq/l) and mortality in ND-CKD patients Jiacong Luo et al. CJASN 2016;11: n=55,266 egfr < 60 Median FU = 2.76 years EKG changes of hyperkalemia are insensitive in guiding therapy in stable patients 242 hospitalized patients All had hyperkalemia ([K+] > 6.0 meq/l) 77% had Renal failure 63 % due to drugs causing HK 49% had hyperglycemia Mean serum [K+] was 6.5±0.6 meq/l EKG changes of hyperkalemia: 46% had any EKG changes suggestive of hyperkalemia Only 36% had peaked T wave Prevalence of ECG changes was independent of the severity of hyperkalemia Acker et al. Arch I Med 1998
11 Treatment of Hyperkalemia Standard approach: Low K diet (2-3 grams/day) Assessment of renal function Review medications and discontinue RAAS inhibitors/ other offending agents (may not be desirable) Correction of metabolic acidosis Treatment of hyperglycemia Enhance urinary excretion: Loop diuretics Mineralocorticoid stimulation: Fludrocortisone (begins to work within 3 hours) but has potent Na retaining action Enhance intestinal K+ excretion by use of potassium binders: Sodium polystyrene sulfonate (Kayexalate) Patiromer ZS-9 Acute Treatment of Hyperkalemia Therapeutic agent Mechanism of action Onset of action Duration of effect IV calcium gluconate Insulin B2-adrenergic agonist (Albuterol) Antagonizes effects of K+ on cardiac muscle membrane Promotes uptake of K+ by cells Promotes uptake of K+ by cells 1-3 min min 30 min 4-6 hours 30 min 2-4 hours Hemodialysis Removal of K from body Immediate > 3 hours
12 Enhance intestinal K+ excretion by use of potassium binders Potassium Concentration in the Intestine Na (meq/l) K (meq/l) meq of K +,* = Duodenum Jejunum Ileum Colon , ,2 16 1,3 * Based on estimated volume of 1.5L, 0.75L, 0.25L, and 0.2L in the duodenum, jejunum, ileum, and colon respectively 2,3 2 1,2 1. Fordtran. Fed Proc Fordtran et al., Am J Dig Sodium Polystyrene sulfonate (Kayexalate) Approved by FDA in 1958 Efficacy not tested in RCTs Given orally or rectally with or without sorbitol Exchanges Na for K, Ca, Mg, and NH4 in the colon Most effective in distal colon and rectum GI side effects: anorexia, nausea, vomiting, diarrhea May cause colonic obstruction, necrosis, and perforation Necrosis may be caused by sorbitol 2009: FDA issued warning against using SPS with 70% sorbitol A premixed suspension of SPS in 33% sorbitol, the only preparation stocked by many hospital pharmacies is commonly used Sterns et al. CJASN 2010
13 33 European ambulatory patients with CKD and mild hyperkalemia ( meq/l) Randomized to 30 g/day SPS without sorbitol for 7 days or placebo SPS superior to placebo in reducing serum K+ level (mean difference: 1.04 meq/l) GI and electrolyte side effects more common in SPS group Lepage et al. CJASN 2015 Kayexalate Combined with Sorbitol Reports Colonic Necrosis with SPS Crystals Watson et al. AJKD 2012 SPS prescribed to 2,194 inpatients 82 inpatient colonic necrosis cases were identified. 3 received oral SPS in 33% sorbitol 30 or fewer days before colonic necrosis Incidence of colonic necrosis: 0.14% in those prescribed SPS versus 0.07% in those not prescribed SPS
14 Sodium Polystyrene sulfonate is non-selective and has greater affinity for Ca & Mg than K Kayexalate (SPS) Ion Binding Potassium, Calcium, and Magnesium Concentration Ratio (1:1:1) 59 Selectivity Ratio* K+ Ca2+ Mg2+ *Selectivity Ratio = [K+] / [Ca+2] + [Mg+2] **Exchange capacity of Ca2+ and Mg2+ was below the set detection limit of 0.05 meq/g; therefore, 0.05 meq/g assumed for calculation purposes. Singh et al., ASH Poster Presentation A New Era for the Treatment of Hyperkalemia 2 new oral drugs to prevent and treat hyperkalemia have been studied in clinical trials: Patiromer sorbitex calcium (RLY5016S-Veltassa) Sodium zirconium cyclosilicate (ZS-9) Trials indicate that both compounds are effective and safe for treatment of hyperkalemia
15 Patiromer Calcium Nonabsorbable synthetic polymer Consists of smooth spherical beads 100 μm in diameter Administered orally as powder suspended in water Does not swell when exposed to water Does not require a laxative to reach the distal colon Binds K+ in exchange for Ca and Mg in distal colon Recommended starting dose 8.4 g/d Can increase dose by 8.4 g/d at weekly intervals. Max dose 25.2 g/d Approved by the FDA in October Efficacy and safety of Patiromer on serum K+ levels in patients with chronic heart failure receiving standard therapy and spironolactone (Placebo) (Patiromer) Pitt et al. Eur Ht J 2011 (Patiromer) Double-blind Placebo-controlled trial N = 120 patients with HF 1/3 rd had DM; egfr 80 All on RAASi or BB Patiromer ( 15 g orally bid) or placebo for 4 weeks All patients started on Spironolactone
16 Initial Treatment Phase: Mean change in serum K+ was meq/l from baseline to week patients with CKD treated with RAASi had serum K+ levels of 5.1 to <6.5 meq/l Patiromer given twice daily (plus low K+ diet with continuation of RAASi) 2-phase study: initial and maintenance phases. Weir M, et al. NEJM. 2015;372: Randomized Withdrawal Phase: During 8 weeks, 94% of patients in patiromer group continued RAASi versus 44% in placebo. Also 60% of the placebo group had recurrence of hyperkalemia (>5.5 meq/ l) vs 15% in patiromer group Weir M, et al. NEJM. 2015;372: patients were enrolled in the second phase Median change in K+ was lower in patiromer group (0 versus 0.72mEq/l
17 Patiromer ( g bid) resulted in significant decreases in serum K+ level after 4 weeks of treatment, lasting through 52 weeks in diabetic CKD patients with mild or moderate Hyperkalemia Phase 2 study Enrolled 306 stages 3 and 4 CKD (15 60 ml/min/1.73m2) patients with T2DM using RAAS blockers Randomized to doses of patiromer according to their baseline K+ level (no placebo group) Bakris et al. JAMA 2015 Mild HK: > meq/l 4.2 g bid meq/l 8.4 g bid g bid Moderate HK:>5.5-<6.0mEq/L 8.4 g bid g bid g bid Most common Adverse Effect of Patiromer
18 Phase 1 study: The first statistically significant serum potassium decline occurred at 7h of Patiromer treatment in CKD patients with hyperkalemia on RAASi meq/l meq/l Bushinsky et al. KI 2015 FDA approval in October 2015 FDA approved patiromer in October 2015 with 2 warnings: Patiromer should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action Patients should take Patiromer at least 6 hours before or after other oral medications FDA updated statement on Nov 27, 2016: FDA removed the Boxed Warning Regarding Drug-Drug Interactions The updated label recommends patients take Patiromer at least 3 hours before or after other oral medications (not the 6-hour separation time)
19 ZS-9: Sodium Zirconium Cyclosilicate ZS-9 is an inorganic, nonabsorbable crystalline compound Exchanges Na+ for K+ in the intestine. Has specific pore size for K+ and NH4+ Highly selective for K+ and NH4+ ions, which are nearly identical in size ZS-9 binds K+ throughout the intestine ZS-9 is insoluble, neither systemically absorbed nor metabolized As ZS-9 can bind NH4+, it can result in an increase in serum bicarbonate. ZS-9 In vitro ion exchange Capacity and Specificity Selectivity ratio SPS: 18/59+24 = 0.2 ZS-9: 96/2+2 = 24 24/0.2 = 120 SPS is more selective for Ca2+ than K+ ZS-9 is 24 times more selective for K+ than Ca2+ and Mg2+ ZS-9 is 120 times more selective for K+ than SPS ZS-9 has 9 times K+ binding capacity than SPS
20 Overview of ZS-9 Clinical Trials 750 To date, almost 2000 patients were enrolled in various clinical trials with ZS-9 *POC: Proof of Concept ZS Pharma R&D- NYC, 2014 Mean K+ levels in patients who received ZS-9 three times daily, as compared with placebo, were significantly reduced at most time points Two-stage, double-blind, phase 3 trial 753 patients (CKD, HF, DM, RAASi) K meq/l Randomly assigned to ZS-9 (1.25 g, 2.5 g, 5 g, or 10 g) or placebo 3x daily for 48 hours (Acute phase). NK patients entered maintenance phase. 72% achieved NK ( mEq/l) at 48 hours were randomly assigned to ZS-9 (as their initial dose) or placebo once daily on days 3 to 14 Packham et al. NEJM Nov 2014
21 HARMONIZE Trial: Mean serum K+ levels over time 258 Patients treated during the open-label phase with ZS 10 g 3 times daily for 48 hours then randomized for 28 days 10 g ZS-9 thrice daily for 6 doses K+ 5.6 meq/l K+ 4.5 meq/l During open-label phase with ZS 10 g 3 times daily for 48 hours, serum K+ was reduced by 1.1 meq/l 258 patients 66% had GFR < 60 70% were on RAASi 36% had HF 66% had DM Kosiborod et al. JAMA 2014 Patients achieving normokalemia (K+: meq/l) randomized to ZS 5, 10 or 15 g/day or placebo for 28 days Mean serum K+: 4.8 on ZS 5 g/d 4.5 on Zs 10 g/d 4.4 on ZS 15 g/d 5.1 on Placebo Mean Serum K+ level over 52-Week Long Term Phase Acute Phase 10 g TID for 1-3 days Maintenance Phase NK patients: 5g/d for 52 week Serum Potassium (meq/l) N = 751 patients
22 ZS-9 given as 10 g significantly reduced the serum K+ level within 1 hour in patients with baseline serum K meq/l Baseline Serum K+ (meq/l) Time (Hour) Subgroup of 45 patients with serum K+ 6 mmol/l (6.1 to 7.2 meq/l) who participated in 2 controlled trials Kosiborod et al. NEJM 2015 * p-value < Adverse Events (n=684) 44
23 Conclusions Hyperkalemia is common in cardiac and CKD patients: Associated with increased risk of death Prevents use of cardiorenal protective agents (RAASi) Current approach is reactive waiting for hyperkalemia to develop before intervention Potential of newer treatment agents: More effective Allow continued use of cardiorenal protective agents (RAASi) Possible preventive use in CKD/ESRD patients Have less serious adverse effects Thank You
Hyperkalemia a silent killer? PD Dr. med. Andreas Kistler Kantonsspital Frauenfeld
Hyperkalemia a silent killer? PD Dr. med. Andreas Kistler Kantonsspital Frauenfeld andreas.kistler@stgag.ch www.nephrologie-thurgau.ch Mr. Hyper K. Lemia charged with serial murder Bild entfernt (copyright)
More informationNew Agents for Treating Hyperkalemia - Can They Help Us Improve Outcomes in HF?
New Agents for Treating Hyperkalemia - Can They Help Us Improve Outcomes in HF? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg
More informationManaging the Yin and Yang of Hyperkalemia and MRAs in Heart Failure
Managing the Yin and Yang of Hyperkalemia and MRAs in Heart Failure Barry Greenberg M.D. Distinguished Professor of Medicine Director, Advanced Heart Failure Treatement Program University of California,
More informationPotassium as a Treatable Biomarker in Cardiovascular Disease: New Keys to Hyperkalemia
Potassium as a Treatable Biomarker in Cardiovascular Disease: New Keys to Hyperkalemia Nicholas Wettersten, MD Associate Professor Heart Failure, Mechanical Circulatory Support and Transplant March 1 st,
More informationBruce Spinowitz, M.D. FACP
Bruce Spinowitz, M.D. FACP Associate Director, Nephrology Vice Chairman, Medicine New York Hospital Queens Clinical Professor of Medicine Weill Medical College of Cornell University McDonough et al. Am
More informationNew Approaches for Treating Hyperkalemia: Why, When and How?
New Approaches for Treating Hyperkalemia: Why, When and How? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor of Medicine Director,
More informationPP-US-DSE Relypsa, Inc. All rights reserved. Relypsa and the Relypsa logo are trademarks of Relypsa, Inc.
1 2 There are 4 main objectives that I d like to cover with you today: First, to review the definition, prevalence, and risk of hyperkalemia in certain populations Second, to review why RAASi are recommended
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 1. To highlight the link between AKI and progression to CKD 2. To discuss the newer agents that have come available for the treatment of hyperkalemia
More informationFaculty. Therapeutic Advances in Hyperkalemia. Disclosures. Learning Objectives 9/7/2018. A Pharmacist s Guide to Patient Identification and Treatment
Faculty Therapeutic Advances in Hyperkalemia Darren W. Grabe, BS, PharmD Associate Professor of Pharmacy Practice Chair, Department of Pharmacy Practice School of Pharmacy and Pharmaceutical Sciences Albany
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationHello, and thank you for joining us for this presentation on novel approaches to understanding risks and treatment of hyperkalemia.
Hello, and thank you for joining us for this presentation on novel approaches to understanding risks and treatment of hyperkalemia. PP-US-DSE-00032. 2015 Relypsa, Inc. All rights reserved. Relypsa and
More informationVELTASSA (patiromer) oral suspension
VELTASSA (patiromer) oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationHYPERKALEMIA. Best Practices in Managing. in Chronic Kidney Disease
+ Best Practices in Managing HYPERKALEMIA in Chronic Kidney Disease Hyperkalemia in Chronic Kidney Disease (CKD) Treatment with RAAS Inhibitors (RAASi) in CKD Diagnosis and Evaluation of Hyperkalemia Treatment
More informationChallenges in RAASi optimization: Hyperkalemia Management Bertram Pitt, M.D.* University of Michigan School of Medicine
Challenges in RAASi optimization: Hyperkalemia Management Bertram Pitt, M.D.* University of Michigan School of Medicine *Consultant: Bayer, Merck, Relypsa+, Pfizer, Astra Zeneca, Boehringer Ingelheim,
More informationSUPPLEMENT TO FIRST REPORT
SUPPLEMENT TO ManagedCare FIRST REPORT PRODUCT BULLETIN This supplement was funded and developed in part, by Relypsa, Inc. MAY 2016 Hyperkalemia, or high potassium, is a potentially lifethreatening condition
More informationLokelma (sodium zirconium cyclosilicate), Veltassa (patiromer)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.42 Subject: Potassium Binders Page: 1 of 5 Last Review Date: November 30, 2018 Potassium Binders Description
More informationElectrolyte Imbalance and Resuscitation. Dr. Mehmet Okumuş Sütçü Imam University Faculty of Medicine Department of Emergency Medicine
Electrolyte Imbalance and Resuscitation Dr. Mehmet Okumuş Sütçü Imam University Faculty of Medicine Department of Emergency Medicine Presentation plan Definition of the electrolyte disturbances Conditions
More informationA Mnemonic for the Treatment of Hyperkalemia. Nick Wolters, PGY1 Resident Grandview Medical Center
A Mnemonic for the Treatment of Hyperkalemia Nick Wolters, PGY1 Resident Grandview Medical Center Hyperkalemia 30 YOF, ESRD, missed 2 dialysis sessions over the last week Potassium level came back at 7
More informationSUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA
SUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA Active Substance: Anatomical Therapeutic Code: MAH or Applicant: Medicinal Product(s) to Which this RMP Refers: Products Concerned (Brand Names): Patiromer
More informationPotassium A NNA VINNIKOVA, M. D.
Potassium A NNA VINNIOVA, M. D. DIVISION OF NEPHROLOGY Graphics by permission from The Fluid, Electrolyte and Acid-Base Companion, S. Faubel and J. Topf, http://www.pbfluids.com Do you want to hear a Sodium
More informationShould we be moving away from Kayexalate (Sodium Polystyrene Sulfonate)?
Should we be moving away from Kayexalate (Sodium Polystyrene Sulfonate)? Shermaine Ngo, LMPS Pharmacy Resident Preceptor: Joanie Tulloch, Emergency Medicine Rotation May 2017 1 Learning Objectives Describe
More informationCardiovascular Pharmacotherapy for Heart Failure Management
Cardiovascular Pharmacotherapy for Heart Failure Management AN UPDATE OF THE LATEST RECOMMENDATIONS AND DATA By: Debby Caraballo, PharmD, PhC, BCPS, AQ-Cardiology Balloon Fiesta Symposium, Albuquerque,
More informationDéveloppement clinique du Patiromer et futures perspectives
Développement clinique du Patiromer et futures perspectives Professor Patrick Rossignol Inserm CIC-P 14-33, CHRU de Nancy-University de Lorraine, ALTIR Disclosures consultant: AstraZeneca, Bayer, CTMA,
More informationA retrospective study of emergency department potassium disturbances: severity, treatment, and outcomes
Clin Exp Emerg Med 2017;4(2):73-79 https://doi.org/10.15441/ceem.16.194 A retrospective study of emergency department potassium disturbances: severity, treatment, and outcomes Adam J Singer 1, Henry C
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationVirtual Mentor American Medical Association Journal of Ethics April 2007, Volume 9, Number 4:
Virtual Mentor American Medical Association Journal of Ethics April 2007, Volume 9, Number 4: 295-299. Clinical pearl Hyperkalemia: newer considerations by Amar D. Bansal and David S. Goldfarb, MD Maintenance
More informationComplications of Acute and Chronic Kidney Disease: A Focus on Hyperkalemia. Mitchell H. Rosner, MD James Tumlin, MD Peter A. McCullough, MD, MPH
Complications of Acute and Chronic Kidney Disease: A Focus on Hyperkalemia Mitchell H. Rosner, MD James Tumlin, MD Peter A. McCullough, MD, MPH Case #1 A 29 year-old male with ESRD secondary to focal segmental
More informationOPTIMISING RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR THERAPY IN HEART FAILURE AND RESISTANT HYPERTENSION: CHALLENGES AND SOLUTIONS
OPTIMISING RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR THERAPY IN HEART FAILURE AND RESISTANT HYPERTENSION: CHALLENGES AND SOLUTIONS This Lorraine University organised, educational event took place
More informationGiovambattista Desideri UO Geriatria Università dell Aquila. Iperkaliema e sideropenia nello scompenso cardiaco
Giovambattista Desideri UO Geriatria Università dell Aquila Iperkaliema e sideropenia nello scompenso cardiaco Kaplan Meier curves for overall survival in (A) men or (B) women with diffrent cancero or
More informationLOKELMA (sodium zirconium cyclosilicate) oral suspension
LOKELMA (sodium zirconium cyclosilicate) oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationHyperkalemia Protect, Shift, and Eliminate
Disclosure Michael C. Thomas reports no relevant financial relationships. Lytes Off in Vegas! The Acute Management of Potassium and Calcium Disorders Program Objectives Design a plan to replace and monitor
More informationNormal range of serum potassium is meq/l true hyperkalemia manifests clinically as : Clinical presentation : muscle and cardiac dysfunction
Potassium Disorders hyperkalemia Potassium is mainly an cation? What is the major physiological role of potassium in the body? What is the major regulatory system of serum potassium level? Which part of
More information4/26/2016. Chronic Kidney Disease for PCPs CLAIRE KASSAKIAN, MD NORTHWEST RENAL CLINIC ANNUAL PRACTICAL ADVANCES IN IM SYMPOSIUM
Chronic Kidney Disease for PCPs CLAIRE KASSAKIAN, MD NORTHWEST RENAL CLINIC ANNUAL PRACTICAL ADVANCES IN IM SYMPOSIUM 1 Disclosures None Overview Epidemiology of CKD in 2016 Hope for HCV Treatment in the
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationHyponatremia and Hypokalemia
Hyponatremia and Hypokalemia Critical Care in the ED March 21 st, 2019 Hannah Ferenchick, MD 1 No financial disclosures 2 1 Outline: 1. Hyponatremia Diagnosis Initial treatment 2. Hyperkalemia Diagnosis
More informationCHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER. The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR
CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR OUTLINE: A journey through CKD Screening for CKD: The why,
More informationEvaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin- Aldosterone System Inhibitors
n REPORT n Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin- Aldosterone System Inhibitors Murray Epstein, MD; Nancy L. Reaven, MA; Susan E. Funk, MBA;
More informationOTE. Lokelma (sodium zirconium cyclosilicate): A Novel Agent for Chronic Hyperkalemia. Personalized Medicine Corner: Incorporating Pharmacogenetics
HAR Vol. 34, Issue 4 January 2019 M A N OTE Established 1985 Lokelma (sodium zirconium cyclosilicate): A Novel Agent for Chronic Hyperkalemia Management Cara Nys, harmd Candidate H yperkalemia, defined
More informationInformRx. Managing Chronic Hyperkalemia. By Pam Scandrett, R.Ph. Risks of High Potassium Levels CLINICAL & REGULATORY NEWS BY PHARMERICA
Managing Chronic Hyperkalemia By Pam Scandrett, R.Ph. CLINICAL & REGULATORY NEWS BY PHARMERICA JAN/FEB 2019 Potassium (K+) is found inside skeletal muscle, liver, and red blood cells. Normal levels of
More informationPosition Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the
More informationDiffuse active ulceration with mucosal necrosis, hemorrhage and pseudomembrane formation Pseudomembranous colitis, Infectious colitis, Acute ischemic
Clinical summary A 34-year-old man with intracerebal and intraventricular hemorrhages Emergency operation Past history : IgA nephropathy chronic renal failure hemodialysis Profuse hematochezia developed
More informationAldosterone synthase inhibitors. John McMurray BHF Cardiovascular Research Centre University of Glasgow
Aldosterone synthase inhibitors John McMurray BHF Cardiovascular Research Centre University of Glasgow Inhibition of aldosterone synthesis is hypothesized to be of benefit to patients with cardiovascular
More informationBasic Fluid and Electrolytes
Basic Fluid and Electrolytes Chapter 22 Basic Fluid and Electrolytes Introduction Infants and young children have a greater need for water and are more vulnerable to alterations in fluid and electrolyte
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationK+ Ann Crawford, RN, PhD, CNS, CEN
Hyperkalemia: Management of a Critical Electrolyte Disturbance K+ Ann Crawford, RN, PhD, CNS, CEN Balancing Fluid Intracellular fluid (ICF) Extracellular fluid (ECF) Intravascular interstitial Hormonal
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationNEW POTASSIUM BINDERS FOR THE TREATMENT OF HYPERKALEMIA: University of Michigan School of Medicine, Ann Arbor, Michigan, USA (BP); Director, ASH
NEW POTASSIUM BINDERS FOR THE TREATMENT OF HYPERKALEMIA: CURRENT DATA AND OPPORTUNITIES FOR THE FUTURE Online Supplement Bertram Pitt, MD and George L. Bakris, MD University of Michigan School of Medicine,
More informationAcute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management
Heart Failure University Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management Sandeep K. Krishnan, MD, Norman E. Lepor, MD, FACC, FAHA, FSCAI Cedars-Sinai
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationFULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES
Steering Committee Kristy N. Greene, PharmD, BCPS, BCCCP Clinical Pharmacist Specialist Neuroscience Critical Care Medicine Emory University Hospital Midtown Atlanta, Georgia Kelly Harbourt, PharmD, BCPS,
More informationPRODUCT INFORMATION RESONIUM A. Na m
PRODUCT INFORMATION RESONIUM A NAME OF THE MEDICINE Non-proprietary Name Sodium polystyrene sulfonate Chemical Structure CH - 2 CH SO 3 Na + n CAS Number 28210-41-5 [9003-59-2] CH 2 CH SO - 3 m DESCRIPTION
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationDrugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events
Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events How does all this play out when it comes to treating patients with type 2 DM who have chronic kidney disease? Therapeutic
More informationDosing Information. The First & Only FDA-approved Spironolactone Oral Suspension P HARM A. Exclusively from
Dosing Information The First & Only FDA-approved Spironolactone Oral Suspension Exclusively from P HARM A The Formulation That s Easy To Prescribe CAROSPIR is an antagonist of aldosterone indicated for:
More informationSODIUM POLYSTYRENE SULFONATE Suspension, USP
SODIUM POLYSTYRENE SULFONATE Suspension, USP DESCRIPTION Sodium Polystyrene Sulfonate Suspension, USP can be administered orally or in an enema. It is a cherryflavored suspension containing 15 grams of
More information578 Index. Eplerenone, 7, 29, 119, 120, 126, 275, 276,
Index A AC. See Adenylate cyclase (AC) ACEI. See Angiotensin converting enzyme inhibitors (ACEI) Adenosine, 179, 180, 182 184, 191, 196 198 Adenosine A1 receptor, 179 183, 186, 190 198 Adenylate cyclase
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationELECTROLYTES RENAL SHO TEACHING
ELECTROLYTES RENAL SHO TEACHING Metabolic Alkalosis 2 factors are responsible for generation and maintenance of metabolic alkalosis this includes a process that raises serum bicarbonate and a process that
More informationSodium Zirconium Cyclosilicate in Hyperkalemia
The new england journal of medicine original article Sodium Zirconium Cyclosilicate in Hyperkalemia David K. Packham, M.B., B.S., M.D., Henrik S. Rasmussen, M.D., Ph.D., Philip T. Lavin, Ph.D., Mohamed
More informationImportant aspects of acid-base disorders
Important aspects of acid-base disorders I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Division of Nephrology, Hypertension and Transplantation University of Florida College
More informationManagement of Acute Kidney Injury in the Neonate. Carolyn Abitbol, M.D. University of Miami Miller School of Medicine / Holtz Children s Hospital
Management of Acute Kidney Injury in the Neonate Carolyn Abitbol, M.D. University of Miami Miller School of Medicine / Holtz Children s Hospital Objectives Summarize the dilemmas in diagnosing & recognizing
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST TAKE HOME MESSAGES FROM RECENT HEART FAILURE CLINICAL TRIALS How to use aldosterone blockers? Faiez Zannad INSERM, U961 and Clinical Investigation Center CHU, Heart
More informationDisclaimer Usage Rights:
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current for the date of this live symposium. All materials contained herein reflect the views of the faculty,
More informationSaint-Antoine Hospital, Paris. Medical Intensive Unit Care. Hafid Ait-Oufella, MD.PhD. Dyscalcemia. Dyskalemia
Dyskalemia Dyscalcemia Hafid Ait-Oufella, MD.PhD. Medical Intensive Unit Care Saint-Antoine Hospital, Paris Potassium K + Molecular weight: 39 1gr K + =2.5mmol Potassium disorders in ICU : Our experience
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationLow Efficacy Diuretics. Potassium sparing diuretics. Carbonic anhydrase inhibitors. Osmotic diuretics. Miscellaneous
University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D Low Efficacy Diuretics 1. Potassium sparing diuretics 2. Carbonic anhydrase inhibitors 3. Osmotic diuretics 4. Miscellaneous
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
COMPARISON OF TREATING METABOLIC ACIDOSIS IN CKD STAGE 4 HYPERTENSIVE KIDNEY DISEASE WITH FRUITS & VEGETABLES OR SODIUM BICARBONATE This was a 1-year, single-center, prospective, randomized, interventional
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationPotassium, Aldosterone, and Hypertension: How Physiology Determines Treatment. Jamie Johnston, MD University of Pittsburgh School of Medicine
Potassium, Aldosterone, and Hypertension: How Physiology Determines Treatment Jamie Johnston, MD University of Pittsburgh School of Medicine No Disclosures Acknowledgements: Evan Ray, MD, PhD Objectives
More informationHypokalemia in Acute Coronary Syndromes and Acute Decompensated Heart Failure
Hypokalemia in Acute Coronary Syndromes and Acute Decompensated Heart Failure Joseph S. Van Tuyl, Pharm.D. PGY1 Pharmacy Resident The University of Oklahoma College of Pharmacy April 4, 2014 Disclosures
More informationNHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults
NHS Grampian Staff Guideline for the Management of Acute Hypokalaemia in Adults Co-ordinators: Medicines Information Pharmacist Consultation Group: See relevant page in guidance Approver: Medicine Guidelines
More informationTreatment guidelines recommend the use of renin
Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics Matthew R. Weir a, Martha R. Mayo b, Dahlia Garza b, Susan A. Arthur b, Lance
More informationABSTRACT. n engl j med 372;3 nejm.org january 15,
The new england journal of medicine established in 1812 january 15, 2015 vol. 372 no. 3 in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors Matthew R. Weir, M.D., George L. Bakris,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationMedical therapy of AKI complications. Refik Gökmen AKI Academy 18 October 2014
Medical therapy of AKI complications Refik Gökmen AKI Academy 18 October 2014 Medical therapy of AKI complications Hyperkalaemia Volume status, fluid therapy Acidosis Calcium & phosphate Bleeding risk
More informationCardiovascular Pharmacotherapy
Cardiovascular Pharmacotherapy Overview Mechanism of cardiovascular drugs Indications and clinical use in cardiology Renin-Angiotensin Inhibitors: Angiotensin-Converting Enzyme Inhibitors, Angiotensin
More informationNovel treatments and update in Heart Failure in CKD
Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients Novel treatments and update in Heart Failure in CKD Annual CVD Mortality (%) 100 David Goldsmith, London, UK 10 GP Male 1 GP
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationβ adrenergic blockade, a renal perspective Prof S O McLigeyo
β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant
More informationEffect of Patiromer on Urinary Ion Excretion in Healthy Adults
Article Effect of Patiromer on Urinary Ion Excretion in Healthy Adults David A. Bushinsky,* David M. Spiegel, Coleman Gross, Wade W. Benton, Jeanene Fogli, Kathleen M. Hill Gallant, Charles Du Mond, Geoffrey
More informationCRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018
CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018 Case 1 Potassium Clearance A 70 kg male is placed on CVVH with a total ultrafiltration rate (effluent rate) of 20 ml/kg/hr. The Blood Flow
More informationCRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018
CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018 Case 1 Potassium Clearance A 70 kg male is placed on CVVH with a total ultrafiltration rate (effluent rate) of 20 ml/kg/hr. The Blood Flow
More informationPotassium regulation. -Kidney is a major regulator for potassium Homeostasis.
Potassium regulation. -Kidney is a major regulator for potassium Homeostasis. Normal potassium intake, distribution, and output from the body. Effects of severe hyperkalemia Partial depolarization of cell
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationDiuretic Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Diuretic Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Potassium-sparing diuretics The Ion transport pathways across the luminal and basolateral
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationMANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE
MANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE Introduction Substantial body of prior CKD clinical data characterizes Bard s unique profile Bard has demonstrated
More informationOutpatient Management of Chronic Kidney Disease for the Internist
Outpatient Management of Chronic Kidney Disease for the Internist Annual Meeting of Maryland Chapter of the American College of Physicians February 3, 2018 MARY (TESSIE) BEHRENS, MD, FACP, FASN, FNKF MID-ATLANTIC
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationkeyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests
www.bpac.org.nz keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests Why do we monitor patients taking diuretics and what do we monitor? Monitoring a person on
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More information